Botanix Founder and Executive Director Matt Callahan:“We are...

Botanix Founder and Executive Director Matt Callahan:

“We are pleased to have enrolled and treated our first patient in the BTX 1308 psoriasis study. The unique design of this patient study which allows us to compare multiple drugs in the same patient at the same time, means that the treatment duration can be shortened, while the quality of data can also be enhanced.”

“BTX 1308 is our third product to commence a patient study in the last 12 months, which demonstrates our ability to rapidly add new indications to the pipeline, as we can leverage the studies already successfully completed with synthetic cannabidiol in acne and atopic dermatitis.

”The Phase 1b patient study will test BTX 1308 against a vehicle (placebo) and an active comparator in15 patients at a single study site in Australia. Because all test articles are compared on psoriasisplaques on the same patient, at the same time, the study protocol is recognised as a powerful proof of concept tool by dermatology companies. The study is expected to take approximately 3 to 4 months to complete and data is expected to be available in 1Q CY2019.